Literature DB >> 8697550

Early neuromuscular recovery characteristics following administration of mivacurium plus vecuronium.

R G Stout1, S J Brull, D Kelly, D G Silverman.   

Abstract

PURPOSE: This study was designed to describe the early recovery characteristics, as well as the speed of onset of neuromuscular block, after a combination of mivacurium and vecuronium.
METHODS: In this controlled, randomized study, 30 consenting ASA I-III patients were assigned to three treatment groups. The "2M2V" group received twice the dose necessary to cause 95% depression of the evoked twitch response (2 x ED95) of mivacurium (0.15 mg.kg-1) plus 2 x ED95 of vecuronium (0.1 mg.kg-1); the "2V" group received 2 x ED95 of vecuronium; and the "4V" group received 4 x ED95 of vecuronium. Evoked neuromuscular responses of the adductor pollicis were assessed with an adductor pollicis force transducer. The time until maximum block and times to 10% and 25% recovery (T10 and T25) in each group were expressed as mean +/- standard deviation and compared using ANOVA.
RESULTS: Onset of block in the 2M2V group was 27% faster than in the 2V group (2.0 +/- 0.6 vs. 2.7 +/- 0.8 min respectively, P < 0.05) and was similar to the 4V group (1.95 +/- 0.3 min, P = NS). The times until 10% recovery were similar in the 2M2V and 4V groups (59.9 +/- 12 vs 68.2 +/- 25 min, P = NS) and were slower than in the 2V groups (37.2 +/- 9 min, P < 0.05). Between T10 and T25 recovery after 2M2V resembled that after 2V (6.7 +/- 3 vs 5.7 +/- 1 min, P = NS) and was faster than after 4V (10.9 +/- 7 min, P < 0.05).
CONCLUSIONS: When 2 x ED95 of mivacurium is added to 2 x ED95 of an intermediate or long-acting relaxant, recovery after T10 will proceed as if one had administered the longer-acting agent alone.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8697550     DOI: 10.1007/BF03011714

Source DB:  PubMed          Journal:  Can J Anaesth        ISSN: 0832-610X            Impact factor:   5.063


  12 in total

1.  Tactile evaluation of train-of-four count as an indicator of reliability of antagonism of vecuronium- or atracurium-induced neuromuscular blockade.

Authors:  A F Kopman
Journal:  Anesthesiology       Date:  1991-10       Impact factor: 7.892

2.  Neuromuscular and cardiovascular effects of mivacurium chloride in surgical patients receiving nitrous oxide-narcotic or nitrous oxide-isoflurane anaesthesia.

Authors:  W W Choi; M P Mehta; D J Murray; M D Sokoll; R B Forbes; S D Gergis; M Abou-Donia; J Kirchner
Journal:  Can J Anaesth       Date:  1989-11       Impact factor: 5.063

3.  The clinical neuromuscular pharmacology of mivacurium chloride (BW B1090U). A short-acting nondepolarizing ester neuromuscular blocking drug.

Authors:  J J Savarese; H H Ali; S J Basta; P B Embree; R P Scott; N Sunder; J N Weakly; W B Wastila; H A el-Sayad
Journal:  Anesthesiology       Date:  1988-05       Impact factor: 7.892

4.  Mivacurium chloride (BW B1090U)-induced neuromuscular blockade during nitrous oxide-isoflurane and nitrous oxide-narcotic anesthesia in adult surgical patients.

Authors:  S Weber; B W Brandom; D M Powers; J B Sarner; S K Woelfel; D R Cook; V J Foster; B F McNulty; J N Weakly
Journal:  Anesth Analg       Date:  1988-06       Impact factor: 5.108

Review 5.  Clinical assessment of neuromuscular transmission.

Authors:  J Viby-Mogensen
Journal:  Br J Anaesth       Date:  1982-02       Impact factor: 9.166

6.  The cardiovascular effects of mivacurium chloride (BW B1090U) in patients receiving nitrous oxide-opiate-barbiturate anesthesia.

Authors:  J J Savarese; H H Ali; S J Basta; R P Scott; P B Embree; W B Wastila; M M Abou-Donia; C Gelb
Journal:  Anesthesiology       Date:  1989-03       Impact factor: 7.892

7.  Pharmacokinetics of mivacurium in normal patients and in those with hepatic or renal failure.

Authors:  D R Cook; J A Freeman; A A Lai; Y Kang; R L Stiller; S Aggarwal; J C Harrelson; R M Welch; B Samara
Journal:  Br J Anaesth       Date:  1992-12       Impact factor: 9.166

8.  Synergism between atracurium and mivacurium compared with that between vecuronium and mivacurium.

Authors:  L Jalkanen; O A Meretoja; T Taivainen; B W Brandom; B Dayal
Journal:  Anesth Analg       Date:  1994-11       Impact factor: 5.108

9.  In vitro metabolism of mivacurium chloride (BW B1090U) and succinylcholine.

Authors:  D R Cook; R L Stiller; J N Weakly; S Chakravorti; B W Brandom; R M Welch
Journal:  Anesth Analg       Date:  1989-04       Impact factor: 5.108

10.  Pharmacodynamics of vecuronium in patients with and without renal failure: a meta-analysis.

Authors:  C Beauvoir; P Peray; J P Daures; J L Peschaud; F D'Athis
Journal:  Can J Anaesth       Date:  1993-08       Impact factor: 5.063

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.